{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:47:13Z","timestamp":1785163633366,"version":"3.55.0"},"reference-count":34,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Cancers"],"abstract":"<jats:p>Upper tract urothelial carcinoma (UTUC) is a rare malignancy that accounts for a small minority of all urothelial cancers. Historically, treatment recommendations for UTUC have been extrapolated from bladder cancer trials due to limited high-quality, UTUC-specific evidence. However, emerging data has shown how UTUC exhibits distinct biological, molecular, and clinical features compared to bladder cancer. In this piece, we provide an analysis of the current evidence supporting adjuvant chemotherapy and immunotherapy for UTUC. We discuss landmark trials such as the POUT trial for adjuvant chemotherapy, as well as pivotal trials such as CheckMate 274, IMvigor 010 and AMBASSADOR that examine the role of adjuvant immunotherapy for UTUC. Additionally, we briefly highlight advances in cancer genetics and the emerging use of circulating tumor DNA as a potential biomarker. While there has been significant progress made in adjuvant treatments for UTUC, substantial knowledge gaps remain. Clinical trials using UTUC-specific populations will be critical in improving outcomes and personalizing care for this patient population.<\/jats:p>","DOI":"10.3390\/cancers17193226","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T14:18:28Z","timestamp":1759501108000},"page":"3226","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Adjuvant Chemotherapy and Immunotherapy in Upper Tract Urothelial Carcinoma: Where Do We Stand?"],"prefix":"10.3390","volume":"17","author":[{"given":"Samuel","family":"Carbunaru","sequence":"first","affiliation":[{"name":"Department of Urology, NYU Langone School of Medicine, New York, NY 10016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Rich","sequence":"additional","affiliation":[{"name":"Department of Urology, NYU Langone School of Medicine, New York, NY 10016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie S.","family":"Murray","sequence":"additional","affiliation":[{"name":"Department of Urology, NYU Langone School of Medicine, New York, NY 10016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"ref_1","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00345-016-1928-x","article-title":"Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)","volume":"35","author":"Soria","year":"2017","journal-title":"World J. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1200\/JCO.23.02679","article-title":"Understanding Adjuvant Therapy for Upper Tract Urothelial Carcinoma","volume":"42","author":"Berg","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1200\/JCO.2017.35.6_suppl.361","article-title":"Molecular characterization of urothelial carcinoma of bladder and upper urinary tract","volume":"35","author":"Hwang","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S248","DOI":"10.21037\/tau.2018.05.07","article-title":"The complex relationship between upper urinary tract and bladder cancer: Clinical and predictive issues","volume":"7","author":"Sanguedolce","year":"2018","journal-title":"Transl. Androl. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.eururo.2015.07.039","article-title":"Genomic characterization of upper tract urothelial carcinoma","volume":"68","author":"Sfakianos","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.eururo.2017.05.048","article-title":"Comprehensive genomic characterization of upper tract urothelial carcinoma","volume":"72","author":"Moss","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","article-title":"Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling","volume":"10","author":"Robinson","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1464-410X.2009.08818.x","article-title":"Temporal stage and grade migration in surgically treated patients with upper tract urothelial carcinoma","volume":"105","author":"Lughezzani","year":"2010","journal-title":"BJU Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/JU.0000000000003480","article-title":"Diagnosis and management of non-metastatic upper tract urothelial carcinoma: AUA\/SUO guideline","volume":"209","author":"Coleman","year":"2023","journal-title":"J. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"New Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/JU.0000000000000644","article-title":"Phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high grade upper tract urothelial carcinoma","volume":"203","author":"Margulis","year":"2020","journal-title":"J. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1200\/JCO.22.00763","article-title":"Multicenter phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma","volume":"41","author":"Coleman","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102224","DOI":"10.1016\/j.clgc.2024.102224","article-title":"Analysis of neoadjuvant chemotherapy utilization, pathologic response, and overall survival in upper tract urothelial carcinoma","volume":"22","author":"Xu","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Tae, J.H., Ha, M.S., Chi, B.H., Chang, I.H., Kim, T.-H., Myung, S.C., Nguyen, T.T., Kim, M., Lee, K.-E., and Kim, Y. (2022). Neoadjuvant versus adjuvant chemotherapy in upper tract urothelial carcinoma: A nationwide cohort study. BMC Urol., 22.","DOI":"10.1186\/s12894-022-01112-6"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): A phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.23.01659","article-title":"Improved disease-free survival with adjuvant chemotherapy after nephroureterectomy for upper tract urothelial cancer: Final results of the POUT trial","volume":"42","author":"Birtle","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"New Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): A multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"New Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1200\/JCO-25-00179","article-title":"Safety and efficacy of neoadjuvant durvalumab plus gemcitabine\/cisplatin or carboplatin in patients with operable high-risk upper tract urothelial carcinoma: The iNDUCT trial","volume":"43","author":"Chevallier","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e1395","DOI":"10.1002\/onco.13839","article-title":"Comparison of genomic characterization in upper tract urothelial carcinoma and urothelial carcinoma of the bladder","volume":"26","author":"Yang","year":"2021","journal-title":"Oncologist"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/archinte.1966.03870080050009","article-title":"Hereditary factors in cancer: Study of two large Midwestern kindreds","volume":"117","author":"Lynch","year":"1966","journal-title":"Arch. Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00073","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"1","author":"Bonneville","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Thouvenin, J., Mart\u00ednez Chanz\u00e1, N., Alhalabi, O., Lang, H., Tannir, N.M., Barth\u00e9l\u00e9my, P., and Malouf, G.G. (2021). Efficacy of immune checkpoint inhibitors in upper tract urothelial carcinomas: Current knowledge and future directions. Cancers, 13.","DOI":"10.3390\/cancers13174341"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.6004\/jnccn.2020.7680","article-title":"Tumor mutational burden and mismatch repair deficiency discordance as a mechanism of immunotherapy resistance","volume":"19","author":"Bielska","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Scherrer, E., Kang, A., Bloudek, L.M., and Koshkin, V.S. (2022). HER2 expression in urothelial carcinoma, a systematic literature review. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1011885"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"TPS717","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS717","article-title":"Phase 3 open-label, randomized, controlled study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001)","volume":"42","author":"Galsky","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1200\/JCO.2025.43.16_suppl.4590","article-title":"Efficacy and safety of disitamab vedotin (RC48) combined with toripalimab as adjuvant therapy after radical surgery for patients with HER2-overexpression upper tract urothelial cancer (UTUC): A single-arm, prospective, phase 2 clinical trial","volume":"43","author":"Liu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41416-020-01047-5","article-title":"Clinical relevance of blood-based ctDNA analysis: Mutation detection and beyond","volume":"124","author":"Keller","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e471912","DOI":"10.1200\/EDBK-25-471912","article-title":"Current and Future Role of Circulating DNA in the Diagnosis and Management of Urothelial Carcinoma","volume":"45","author":"Bellmunt","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_33","first-page":"13","article-title":"Disease-free survival and overall survival in patients with high-risk muscle-invasive bladder cancer who have persistent circulating tumor DNA-negative biomarker status post-cystectomy: IMvigor011 study surveillance analysis","volume":"43","author":"Bellmunt","year":"2025","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1038\/s41591-024-03091-7","article-title":"Pembrolizumab for advanced urothelial carcinoma: Exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial","volume":"30","author":"Powles","year":"2024","journal-title":"Nat. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/19\/3226\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T14:22:39Z","timestamp":1759501359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/19\/3226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":34,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["cancers17193226"],"URL":"https:\/\/doi.org\/10.3390\/cancers17193226","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]}}}